Monoklonal Antikorlar ve Tedavide Kullanımı

Bağışıklık sistemi vücudu hastalık yapıcı patojenlere karşı koruyan temel savunma sistemidir. Bu savunma sistemi farklı mekanizmalarla etkili olmaktadır. Bağışıklık sistemi, antijen adı verilen vücudun kalıtsal yapısına yabancı olan her türlü yapıya karşı etki gösterir. Vücuda dışarıdan gelen hastalık etkenleri öncelikle doğal bariyerlerle karşılaşmaktadır. Doğal bariyerleri aşmayı başaran etkenler kemik iliği, timus, lenf bezleri ve dalak gibi özelleşmiş organlarda üretilen savunma hücreleri ile karşılaşır. İlk aşamada makrofajlar ve fagositler devreye girer daha sonraki aşamada ise B ve T lenfositleri sürece dahil olurlar. B lenfositlerinden salgılanan antikorlar bağışık sisteminin en önemli savunma mekanizmalarından birini oluşturmaktadır. Antikor moleküllerinin vücudun savunmasındaki bu önemi bilim insanlarını bu alanda çalışmaya yöneltmiştir. Bu doğrultuda 1975 yılında Georges Köhler ve Cesar Milstein, koyun alyuvarları ile immunize ettikleri farelerin B lenfositleri ile fare myeloma hücrelerini birleştirerek oluşturdukları hibrit hücreler ile yeni bir tedavi stratejisinin kapısını açmışlardır. Bu hibrit hücreler sadece istenen antijene bağlanan monoklonal antikor sentezleyebilme yeteneğine sahiptir. Monoklonal antikorlar tıp dünyasında hastalıkların teşhisi, tedavisi ve biyokimyasal analizler gibi birçok alanda kullanmaktadır. Günümüzde hala monoklonal antikora dayalı tedavi ve tedavi seçenekleri üzerinde çalışmalar devam etmektedir. Bu derlemede monoklonal antikorlar ve tedavide kullanımı üzerine genel bilgiler verilecektir.

Monoclonal Antibodies and Their Uses in Therapy

Immune system is the basic defense system that protects the body against disease causing pathogens. The immun system use the most effective mechanisms and protects body against foreign materials called antigen. The antigens encounter primarily natural barriers. The antigens that cross natural barriers encounter immune cells in organs such as bone marrow, lymph nodes, spleen and thymus. In the first stage, macrophages and phagocytes become active, and in the next stage, B and T lymphocytes are involved in the process. Antibodies produced by B lymphocytes form one of the most important defense mechanism in immune system. This importance of antibody molecules in the immun system has led to scientists work in the field. In 1975, Georges Köhler and Cesar Milstein combined B lymphocytes from mice immunized with sheep red blood cells with the infinite growth of mouse myeloma cells to obtain monoclonal antibody-producing hybrid cells and paving the way for the development of therapeutic antibodies. This hybrid cells have ability to produce monoclonal antibodies just binding only to the desired antigen. Monoclonal antibodies have been used in many areas such as diagnosis, treatment and biochemical analysis of diseases worlwide. Nowadays, studies on monoclonal antibody-based treatment and treatment options are still ongoing. This review will focus on monoclonal antibodies and their uses in therapy.

PDF

___

Abbas AK, Lichtman AH, Pillai S. 2015. Cellular and molecular immunology. Philadelphia, PA: Elsevier Saunders. ISBN 9780323286459 0323286453
Agerberth B, Guðmundsson GH. 2006. Host antimicrobial defence peptides in human disease. In: Schaffer W, (editors) Antimicrobial peptides and human disease. Berlin, Springer, pp: 67-90 ISBN 978-3-540-29916-5
Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA, Abdelsamed HA, McGuire DJ, Alexe G, Nagar S, McCausland MM, Gupta S, Tata P, Haining WN, McElrath MJ, Zahng D Hu B, Greenleaf WJ, Goronzy JJ, Mulligan MJ, Hellerstein M, Ahmed R. 2017. Origin and differentiation of human memory CD8 T cells after vaccination. Nature, 552: 362-367. https://doi.org/10.1038/ nature24633
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. 2002. Molecular Biology of the Cell. New York: Garland Science. ISBN-10: 0815332882
AlDallal SM. 2017. Ofatumumab- a valid treatment option for chronic lymphocytic leukemia patients. Therapeutics and Clinical Risk Management, 13: 905–907. doi: 10.2147/TCRM.S140023
Almagro JC, Fransson J. 2008. Humanization of antibodies. Frontiers in Bioscience., 13(1), 1619-1633. PMID: 17981654
Amarasekera M. 2011. Immunoglobulin E in health and disease. Asia Pacific Allergy, 1(1): 12-15. doi: 10.5415/apallergy.2011.1.1.12
Ansar W, Ghosh S. 2013. Monoclonal antibodies: a tool in clinical research. Indian Journal of Clinical Medicine 4, S11968. https://doi.org/10.4137/IJCM.S11968
Arakelov A, Lakkis FG. 2000. The alloimmune response and effector mechanisms of allograft rejection. In Seminars in nephrology, 20(2): 95-102. PMID: 10746853
Baron J, Wang ES. 2018. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert review of clinical pharmacology, 11(6): 549-559. doi: 10.1080/17512433.2018.1478725
Bayer V. 2019. An Overview of Monoclonal Antibodies. In Seminars in oncology nursing., 35(5): 150927. https://doi. org/10.1016/j.soncn.2019.08.006
Beck G, Habicht GS. 1996. Immunity and the invertebrates. Scientific American., 275(5): 60-66. doı: 10.1038/scientificamerican1196-60.
Bou-Assaly W, Mukherji S. 2010. Cetuximab (erbitux). American Journal of Neuroradiology, 31(4): 626‐627. doı: 10.3174/ajnr.A2054
Boudreau CM, Alter G. 2019. Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine. Front Immuno., 10, 440. doi: 10.3389/fimmu.2019.00440
Breedveld FC. 2000. Therapeutic monoclonal antibodies. Lancet., 355(9205): 735-740. doi:https://doi.org/10.1016/ S0140-6736(00)01034-5
Bruno V, Battaglia G, Nicoletti F. 2011. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurological sciences, 31(3): 283-288. doi: 10.1007/s10072-010-0382-6
Burnet FM. 1957. A modification of Jerne's theory of antibody production using the concept of clonal selection. Australian Journal of Science, 20(3): 67-9. doi: 10.3322/canjclin.26.2.119
Cheung MC, Maceachern JA, Haynes AE, Meyer RM, Imrie K. 2009. Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 131I–Tositumomab in lymphoma. Current Oncology., 16(5): 32. PMID: 19862360
Chiavenna SM, Jaworski JP, Vendrell A. 2017. State of the art in anti-cancer mAbs. Journal of biomedical science, 24(1): 15. https://doi.org/10.1186/s12929-016-0311-y
Chidharla A, Kasi A. 2020. Cetuximab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing., Available from: https://www.ncbi.nlm.nih.gov/books/NBK459293/ (Erişim Tarihi:10.05.2020)
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. 2019. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies, 8(4): 55. doi: 10.3390/antib8040055
Coulson A, Levy A, Gossell-Williams M. 2014. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. The West Indian medical journal, 63(6): 650–654. https://doi.org/10.7727/wimj.2013.241
Cunningham AF, Flores-Langarica A, Bobat S, Dominguez Medina CC, Cook CN, Ross EA, Henderson IR. 2014. B1b cells recognize protective antigens after natural infection and vaccination. Frontiers in immunology, 5: 535. doi: 10.3389/fimmu.2014.00535
Damelang T, Rogerson SJ, Kent SJ, Chung AW. 2019. Role of IgG3 in infectious diseases. Trends in Immunology, 40(3): 197-211. doi:https://doi.org/10.1016/j.it.2019.01.005.
Dang TO, Ogunniyi A, Barbee MS, Drilon A. 2016. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert review of anticancer therapy, 16(1): 13–20. https://doi.org/10.1586/14737140.2016.1123626
De Smet K, Contreras R. 2005. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnology letters., 27(18): 1337-1347.
De Souza AW, Mesquita Júnior D, Araújo JA, Catelan TT, Cruvinel WDM, Andrade LE. 2010. Immune system: part III. The delicate balance of the immune system between tolerance and autoimmunity. Revista Brasileira de Reumatologia., 50(6): 665-79. PMID: 21243307
De Taeye SW, Rispens T, Vidarsson G. 2019. The Ligands for Human IgG and Their Effector Functions. Antibodies, 8(2): 30. https://doi.org/10.3390/antib8020030
Dean L. 2015. Trastuzumab (herceptin) therapy and ERBB2 (HER2) genotype. In Medical Genetics Summaries. NCBI., https://www.ncbi.nlm.nih.gov/books/NBK310376/ (Erişim Tarihi: 10.05.2020)
Deeks ED. 2019. Polatuzumab Vedotin: First Global Approval. Drugs, 79(13), 1467-1475. https://doi.org/10.1007/s40265-019-01175-0
Delacroix DL, Dive C, Rambaud JC, Vaerman JP. 1982. IgA subclasses in various secretions and in serum. Immunology., 47(2): 383-385. PMID: 7118169
Denosumab (Xgeva) [Internet] 2016. Ottawa (ON): CADTH., Available from: https://www.ncbi.nlm.nih.gov/books /NBK409947 (Erişim Tarihi: 10.05.2020).
Duarte J, Deshpande P, Guiyedi V, Mécheri S, Fesel C, Cazenave PA, Pied S. 2007. Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status. Malaria journal, 6(1): 1-13. doi: 10.1186/1475-2875-6-1
Durmaz EÖ. 2013. B hücre aktivasyonu ve antikor üretimi. Archives of the Turkish Dermatology and Venerology/Turkderm., 47(1): 24-7. doı: 10.4274/turkderm.47.s4
Ecker DM, Jones SD, Levine HL. 2015. The therapeutic monoclonal antibody market. In MAbs 7(1): 9-14. doi: 10.4161/19420862.2015.989042.
Ehrenstein MR, Cook HT, Neuberger MS. 2000. Deficiency in serum immunoglobulin (Ig) M predisposes to development of IgG autoantibodies. The Journal of experimental medicine., 191(7): 1253-1258. doi: 10.1084/jem.191.7.1253.
Erb KJ. 2007. Helminths, allergic disorders and IgE‐mediated immune responses: where do we stand? European journal of immunology, 37(5): 1170-1173. doi: 10.1002/eji.2007373 14.
Fala L. 2016. Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer. American health and drug benefits, 9(Spec Feature), 119-122. PMID: 27668058
Fillatreau S. 2018. Natural regulatory plasma cells. Current opinion in immunology., 55: 62-66. doi: 10.1016/j.coi.2018. 09.012
Forthal DN. 2014. Functions of Antibodies. Microbiology spectrum., 2(4): 1–17. PMID: 25215264
Friedberg JW, Fisher RI. 2004. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma. Expert review of anticancer therapy., 4(1): 18-26. PMID: 19862360
Ganguly S, Choudhary S, Kataria AK, Bhati T. 2018. Production of Monoclonal Antibodies. In: Ganguly S, Choudhary S. (editors). Delhi, India, Recent Research Trends in Veterinary Sciences and Animal Husbandry, AkiNik Publications, pp. 33-40. DOI: 10.22271/ed.book04.a03
Gemmete JJ, Mukherji SK. 2011. Panitumumab (vectibix). American journal of neuroradiology, 32(6): 1002-1003. doı: https://doi.org/10.3174/ajnr.A2601
Gerriets V, Kasi A. 2019. Bevacizumab. In StatPearls [Internet]. StatPearls Publishing https://www.ncbi.nlm.nih.gov/books/ NBK482126/ (Erişim Tarihi: 10.05.2020)
Geskin LJ. 2015. Monoclonal Antibodies. Dermatologic clinics, 33(4): 777‐786. doı: 10.1016/j.det.2015.05.015
Glassman PM, Balthasar JP. 2014. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer biology and medicine., 11(1): 20-33. doi: 10.7497/j.issn.2095-3941.2014.01.002
Godwin L, Crane JS. 2019. Biochemistry, Immunoglobulin E (IgE). In StatPearls [Internet]. StatPearls, https://www.ncbi. nlm.nih.gov/books/NBK541058/ (Erişim Tarihi: 10.05.2020).
Graziani G, Tentori L, Navarra P. 2012. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological research., 65(1): 9-22. doı: 10.1016/j.phrs.2011.09.002
Green L. 2014. Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies. Current drug discovery technologies., 11(1): 74-84. doı: 10.2174/15701638113109990038
Grönwall C, Vas J, Silverman GJ. 2012. Protective roles of natural IgM antibodies. Frontiers in immunology, 3: 66. doi: 10.3389/fimmu.2012.00066
Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. 2005. Acute phase reaction and acute phase proteins. Journal of Zhejiang University. Science, 6(11): 1045-1056. doi: 10.1631/jzus.2005.B1045
Guan M, Zhou YP, Sun JL, Chen SC. 2015. Adverse events of monoclonal antibodies used for cancer therapy. BioMed Research International., 2015, 1-13. doı: 10.1155/2015/428169
Guo L, Zhang H, Chen B. 2017. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 8(3): 410-416. https://doi.org/10.7150/jca.17144
Gutcher I, Becher B. 2007. APC-derived cytokines and T cell polarization in autoimmune inflammation The Journal of clinical investigation, 117(5): 1119-1127. doi: 10.1172/JCI31720.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. 2010. The safety and side effects of monoclonal antibodies. Nature reviews Drug discovery, 9(4): 325-338. doi: 10.1038/nrd3003
Hanson LA. 1961. Comparative immunological studies of the immune globulins of human milk and of blood serum. International Archives of Allergy and Immunology, 18(5): 241-267. doi: 10.1159/000229177
Hoffman W, Lakkis FG, Chalasani G. 2016. B cells, antibodies, and more. Clinical Journal of the American Society of Nephrology., 11(1): 137-154. doi: 10.2215/CJN.09430915
Hulett MD, Hogarth PM. 1998. The second and third extracellular domains of FcγRI (CD64) confer the unique high affinity binding of IgG2a. Molecular immunology, 35(14-15): 989-996. https://doi.org/10.1016/S0161-5890(98)00069-8
Iwasaki A, Medzhitov R. 2015. Control of adaptive immunity by the innate immune system. Nature immunology., 16(4): 343-353. doı: 10.1038/ni.3123
Jain S, Gautam V, Naseem S. 2011. Acute-phase proteins: As diagnostic tool. Journal of Pharmacy and Bioallied Sciences., 3(1): 118-127. doi: 10.4103/0975-7406.76489
Janeway CA Jr, Travers P, Walport M. 2001. The Immune System in Health and Disease. 5th edition. New York: Garland Science; The major histocompatibility complex and its functions. Immunobiology., Available from: https://www.ncbi.nlm.nih.gov/books/NBK27156/ (Erişim Tarihi: 10.05.2020)
Johnson RW, Von Borell E. 1994. Lipopolysaccharide-induced sickness behavior in pigs is inhibited by pretreatment with indomethacin. Journal of Animal Science, 72(2): 309-314. https://doi.org/10.2527/1994.722309x
Junqueira LCU, Carneiro J. 2005. Basic histology: text and atlas. United States: McGraw-Hill Medical. ISBN-10: 0071780335
Kaya MN, Caner B, Avcı N. 2018. Onkolojide Yeni Bir Dönem: İmmunokonjugatlar. Kocaeli Tıp Dergisi., 7(1): 25-31. doi: 10.5505/ktd.2018.83997
Kaya S. 2013. Veteriner Farmakoloji. Ankara: Medisan Yayınevi. ISBN 978-975-7774-72-3
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. 2010. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics., 49(8): 493-507. doi: 10.2165/11531280-000000000-00000.
King S, Short M, Harmon C. 2016. Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban. Vascular pharmacology., 78: 10-16. https://doi.org/10.1016/j.vph. 2015. 07.008
Koj A. 1989. The Role of Interleukin‐6 as the Hepatocyte Stimulating Factor in the Network of Inflammatory Cytokines. Annals of the New York Academy of Sciences., 557(1): 1-8. doi: 10.1111/j.1749-6632.1989.tb23994.x.
Kumar V, Sharma A. 2010. Neutrophils: Cinderella of innate immune system. International immunopharmacology., 10(11): 1325-1334. https://doi.org/10.1016/j.intimp.2010. 08.012
Kummerfeldt CE. 2014. Raxibacumab: potential role in the treatment of inhalational anthrax. Infection and drug resistance 7, 101–109. https://doi.org/10.2147/IDR.S47305.
Kunkel HG, Prendergast RA. 1966. Subgroups of γA Immune Globulins. Proceedings of the Society for Experimental Biology and Medicine., 122(3): 910-913. https://doi.org /10.3181/00379727-122-31287
Li G, Wang S, Xue X, Qu X, Liu H. 2013. Monoclonal antibody-related drugs for cancer therapy. Drug discoveries and therapeutics, 7(5): 178-184. PMID: 24270381
Liddell E. 2013. Antibodies. In: David W (editor). The Immunoassay Handbook. Elsevier. pp. 245-265. ISBN 978-0-08-097037-0
Liu JK. 2014. The history of monoclonal antibody development–progress, remaining challenges and future innovations. Annals of Medicine and Surgery, 3(4): 113-116. doi: 10.1016/j.amsu.2014.09.001
LiverTox 2012a. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): Monoclonal Antibodies, National Institute of Diabetes and Digestive and Kidney Diseases, Available from: https://www.ncbi. nlm.nih.gov/books/NBK548844/ (Erişim tarihi: 25.05.2020).
LiverTox 2012b Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): Inotuzumab Ozogamicin. National Institute of Diabetes and Digestive and Kidney Diseases, Available from: https://www.ncbi. nlm.nih.gov/books/NBK547906/ (Erişim tarihi: 25.05.2020).
LiverTox 2012c. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): Blinatumomab, National Institute of Diabetes and Digestive and Kidney Diseases, Available from: https://www. ncbi.nlm.nih.gov/books/NBK548198/ (Erişim tarihi: 25.05.2020).
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. 2020. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1): 1-30. https://doi.org/10.1186/s12929-019-0592-z
Mahmuda A, Bande F, Al-Zihiry KJK, Abdulhaleem N, Majid RA, Hamat RA, Abdullah WO, Unyah Z. 2017. Monoclonal antibodies: A review of therapeutic applications and future prospects. Tropical Journal of Pharmaceutical Research., 16(3): 713-722. doi: 10.4314/tjpr.v16i3.29
Mahroof S, Pant G, Rafeek R. 2016. Monoclonal Antıbodıes: An Emergıng Immunotherapy Technology. European Journal of Biomedical and Pharmaceutical sciences., 3(4): 134-143.
Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. 2002. Humoral immunity and long-lived plasma cells. Current opinion in immunology., 14(4): 517-521. doı: 10.1016/S0952-7915(02)00356-4
Markham A. 2016B. Atezolizumab: first global approval. Drugs, 76(12): 1227-1232. doı: 10.1007/s40265-016-0618-8
Markham A, Duggan S. 2018. Cemiplimab: first global approval. Drugs, 78(17): 1841-1846. doı: 10.1007/s40265-018-1012-5
Markham A. 2016A. Elotuzumab: first global approval. Drugs, 76(3): 397-403. doi: 10.1007/s40265-016-0540-0
Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A. 2016. An overview on safety of monoclonal antibodies. Current opinion in allergy and clinical immunology, 16(6): 576-581. doi: 10.1097/ACI.0000000000000315.
McGinty L, Kolesar J. 2012. Dinutuximab for maintenance therapy in pediatric neuroblastoma. American Journal of Health-System Pharmacy., 74(8): 563-567. doı: 10.2146/ajhp160228
McKeage K. 2016. Daratumumab: first global approval. Drugs., 76(2): 275-281. doı: 10.1007/s40265-015-0536-1
Medzhitov R, Janeway Jr CA. 1998. Innate immune recognition and control of adaptive immune responses. In Seminars in immunology., 10(5): 351-353. doı: 10.1006/smim.1998.0136
Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature, 449(7164): 819-826. doı: 10.1038/nature06246
Meisel K, Rizvi SA. 2011. Complications of monoclonal antibody therapy. Rhode Island Medical Journal 94(11): 317. PMID: 22204093
Mishra AK, Mariuzza RA. 2018. Insights into the structural basis of antibody affinity maturation from next-generation sequencing. Frontiers in immunology, 9: 117. doi: 10.3389/fimmu.2018.00117
Modjtahedi H, Ali S, Essapen S. 2012. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. British Medical Bulletin. 104(1): 41-59. doı: 10.1093/bmb/lds032
Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. Clinical microbiology reviews., 22(2): 240-273. doi: 10.1128/CMR.00046-08
Molina H. 2004. Complement and immunity. Rheumatic Disease Clinics of North America., 30(1): 1–18. doi:10.1016/s0889-857x(03)00113-3
Motley MP, Banerjee K, Fries BC. 2019. Monoclonal antibody-based therapies for bacterial infections. Current Opinion in Infectious Diseases, 32(3): 210‐216. doi: 10.1097/QCO.0000000000000539
Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. 2018. Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).
Hematology/Oncology and Stem Cell Therapy 11(3): 187-188. https://doi.org/10.1016/ j.hemonc. 2017.12.004
Newsome BW, Ernstoff MS. 2008. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? British journal of clinical pharmacology., 66(1): 6-19. doi: 10.1111/j.1365-2125.2008.03187.x
Nussenzweig MC, Steinman RM, Gutchinov BODMA, Cohn ZA. 1980. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. Journal of Experimental Medicine, 152(4): 1070-1084. doı: 10.1084/jem.152.4.1070
Omilusik KD, Goldrath AW. 2017. The origins of memory T cells. Nature, 552(7685): 337-339. doi: 10.1038/d41586-017-08280-8
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. 2011. IgG placental transfer in healthy and pathological pregnancies. Clinical and Developmental Immunology, 2012: 1-13. https://doi.org/10.1155/2012 /985646
Pandey S. 2010. Hybridoma technology for production of monoclonal antibodies. Hybridoma, 1(2): 017.
Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP. 2001. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Medical Oncology, 18(2): 99-107. doı: 10.1385/MO:18:2:99
Parihar A, Eubank TD, Doseff AI. 2010. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. Journal of innate immunity, 2(3): 204-215. doı: 10.1159/000296507
Parkin J, Cohen B. 2001. An overview of the immune system. Lancet., 357(9270): 1777-1789. doı:https://doi.org/10.1016/ S0140-6736(00)04904-7
Paul S, Lal G. 2017. The molecular mechanism of natural killer cells functions and its importance in cancer immunotherapy. Frontiers in immunology, 8: 1124. doi: 10.3389/fimmu.2017.01124
Pierpont TM, Limper CB, Richards KL. 2018. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Frontiers in Oncology, 8: 163. doi: 10.3389/fonc.2018.00163
Qamar N, Fuleihan RL. 2014. The hyper IgM syndromes. Clinical Reviews in Allergy and Immunology., 46(2): 120-130. doı: 10.1007/s12016-013-8378-7
Quigley MF, Gonzalez VD, Granath A, Andersson J, Sandberg JK. 2007. CXCR5+ CCR7–CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles. European Journal of Immunology, 37(12): 3352-3362. https://doi.org/10.1002/eji.200636746
Rizzieri D. 2016. Zevalin (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Critical Reviews in Oncology/Hematology, 105: 5-17. doi: 10.1016/j.critrevonc.2016.07.008.
Rogentine Jr GN, Rowe DS, Bradley J, Waldmann TA, Fahey JL. 1966. Metabolism of human immunoglobulin D (IgD). Journal of Clinical Investigation, 45(9): 1467-1478. doi: 10.1172/JCI105454
Román VRG, Murray JC, Weiner LM. 2014. Antibody-dependent cellular cytotoxicity (ADCC) In: Margaret E. Ackerman, Falk Nimmerjahn (editors). Antibody Fc. Cambridge, Massachusetts, USA: Academic press, s: 1-27. ISBN 978-0-12-394802-1
Samaranayake L. 2012. Essential Microbiology for Dentistry. London, UK: Churchill Livingstone, Elsevier. ISBN 9780702074356
Safdari Y, Farajnia S, Asgharzadeh M, Khalili M. 2013. Antibody humanization methods–a review and update. Biotechnology and Genetic Engineering Reviews, 29(2): 175-186. doı: 10.1080/02648725.2013.801235
Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Krämer BK, Schlitt HJ. 2007. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbeck's Archives of Surgery., 392(5): 511-523. doi: 10.1007/s00423-007-0188-z.
Scott AM, Allison JP, Wolchok JD. 2012. Monoclonal antibodies in cancer therapy. Cancer Immunity Archive, 12(1). PMID: 22896759
Selimoğlu S, Kasap M, Akpınar G, Karadenizli A. 2016. Monoklonal Antikor Teknolojisinin Dünü, Bugünü ve Geleceği. Kocaeli Üniversitesi Sağlık Bilimleri Dergisi, 2(1): 6-14. https://doi.org/10.30934/kusbed.358477
Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G. 1980. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. The New England Journal of Medicine., 303(4): 178-182. doı: 10.1056/NEJM198007243030402
Silva MT, Correia-Neves M. 2012. Neutrophils and macrophages: the main partners of phagocyte cell systems. Frontiers in immunology, 3: 174. doi: 10.3389/fimmu.2012.00174
Stark GR, Taylor WR. 2004. Analyzing the G2/M checkpoint. Methods in Molecular Biology., 280, 51‐82. doı: 10.1385/1-59259-788-2:051
Stavnezer J, Schrader CE. 2014. IgH chain class switch recombination: mechanism and regulation. Journal of Immunology., 193(11): 5370-5378. doı: 10.4049/jimmunol.1401849
Suzuki M, Kato C, Kato A. 2015. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. Journal of Toxicologic Pathology, 28(3): 133-139. doi: 10.1293/tox.2015-0031.
Şakalar Ç, İzgi K, Canatan H. 2013. Kanser immün terapi ve monoklonal antikorlar. Fırat Üniversitesi Sağlık Bilimleri Dergisi., 27(2): 105-111.
Tabll A, Abbas AT, El-Kafrawy S, Wahid A. 2015. Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World Journal of Hepatology., 7(22): 2369–2383. doı: 10.4254/wjh.v7.i22. 2369
Tavakolpour S. 2016. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors and Clinical Investigation., 3(1): e1173. doi: 10.14800/rci.1173
Thachil J. 2016. Antiplatelet therapy- a summary for the general physicians. Clinical Medicine., 16(2): 152–160. doi: 10.7861/clinmedicine.16-2-152
Thau L, Mahajan K. 2020. Physiology, Opsonization. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing https://www.ncbi.nlm.nih.gov/books/NBK5342 15/ (Erişim tarihi: 28.05.2020).
Tomasi Jr TB, Tan EM, Solomon A, Prendergast RA. 1965. Characteristics of an immune system common to certain external secretions. Journal of Experimental Medicine., 121(1): 101-124. doı: 10.1084/jem.121.1.101
Turvey SE, Broide DH. 2010. Innate immunity. The Journal of Allergy and Clinical Immunology, 125(2): S24-S32. doı: 10.1016/j.jaci.2009.07.016
Van de Donk NW, Dhimolea E. 2012. Brentuximab vedotin. mAbs., 4(4): 458–465. doi: 10.4161/mabs.20230
Van Kooten C, Banchereau J. 1997. Functions of CD40 on B cells, dendritic cells and other cells. Current Opinion in Immunology., 9(3): 330-337. https://doi.org/10.1016/S0952-7915(97)80078-7
Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Frontiers in Immunology, 5, 520. https://doi.org/10.3389/fimmu.2014. 00520
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 2008. Functions of natural killer cells. Nature Immunology., 9(5), 503-510. doı: 10.1038/ni1582
Wang LD, Clark MR. 2003. B‐cell antigen‐receptor signalling in lymphocyte development. Immunology., 110(4): 411-420. doi: 10.1111/j.1365-2567.2003.01756.x
Wang TS, Byrne PJ, Jacobs LK, Taube JM. 2011. Merkel cell carcinoma: update and review. Seminars in Cutaneous Medicine and Surgery, 30(1): 48. doı: 10.1016/j.sder.2011.02.001
Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. 2015. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in Immunology, 6: 368. doı: 10.3389/fimmu.2015.00368
Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences., 96(1): 1-26. https://doi.org/10.1002/jps.20727
Wang-Lin SX, Balthasar JP. 2018. Pharmacokinetic and pharmacodynamic consideration for the use of monoclonal antibodies in the treatment of bacterial infections. Antibodies., 7(1): 5-25. doi: 10.3390/antib7010005
Wykes M. 2003. Why do B cells produce CD40 ligand? Immunology and Cell Biology., 81(4): 328-331. https://doi.org/10.1046/j.1440-1711.2003.01171.x
Youngblood B, Hale JS, Kissick HT, Ahn E, Xu X, Wieland A, Araki K, West EE, Ghoneim HE, Fan Y, Dogra P, Davis CW, Konieczny BT, Anita R, Cheng X, Rafi A. 2017. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature., 552(7685): 404-409. doi: 10.1038/nature25144
Zhou H, Wu L. 2017. The development and function of dendritic cell populations and their regulation by miRNAs. Protein Cell, 8(7): 501-513. https://doi.org/10.1007/s13238-017-0398-2